SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Shares of MLTX are trending amid a steep decline following mixed results from a Phase 3 trial, leading to significant community discussion around potential short covering and whether the market has overreacted. Some investors are speculating about a possible acquisition by Merck, while others are assessing the company's cash reserves and future prospects. The conversation highlights the volatile nature of biotech stocks and the high-risk, high-reward potential in the sector.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is trending as it reached new all-time highs, driven by optimism around its prediction markets business and expansion into new fintech services. Community members are actively discussing the stock's potential to continue its impressive run, while some caution against overvaluation and a possible pullback. Bullish sentiment is fueled by strong financials and the stock's inclusion in the S&P 500.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

APDN is trending following news of a $58M private placement to initiate a BNB-focused digital asset strategy, with plans to change its ticker to BNBX; the stock experienced multiple trading halts as a result. The community is discussing the potential for a significant price increase, with some drawing comparisons to other low-float runners and noting Scaramucci's involvement as an advisor. This activity occurs amid broader speculation about the company's strategic shift towards digital assets.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as investors eagerly anticipate the release of its Preliminary Feasibility Study (PFS), with some speculating its imminent arrival could trigger a significant price surge. Bullish sentiment is fueled by increasing volume, government backing, and potential short squeezes, while community members express excitement about the company's long-term prospects in the lithium and battery recycling sectors.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals ($AUPH) is trending due to an ex-FDA employee's LinkedIn post questioning the safety and efficacy of their drug Lupkynis, sparking concerns about potential market manipulation. The community is debating the validity of the claims, the company's response, and possible legal action. Some investors believe this is a strategic move to lower the price before a buyout, while others worry about the drug's reputation and future sales.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is gaining traction as an AI-themed memecoin associated with Elon Musk's Grok AI, with the community rallying behind its potential. Some are pointing to a tight float and potential catalyst related to NXXT, while others highlight the strong community and growing number of holders. It is also being mentioned in the context of other trending coins like $UPDOG.X and $RAGE.X.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a crypto focused on community, freedom, and culture, with some suggesting potential links to broader cannabis industry developments. Community members are actively discussing its vision for growth and its potential as a culture coin. Some users are also discussing where to purchase the coin and celebrating its trending status.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending as traders discuss its recent price surge and potential for further gains, with the community focusing on breaking the $12 resistance level. Some speculate about a short squeeze due to the stock's low float and high trading volume. Others believe the stock is benefitting from funds rotating into policy winning names.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as investors debate whether its recent dip presents a buying opportunity or signals deeper concerns about growth and valuation, especially when compared to competitors like Chipotle. Community discussions revolve around the stock's support levels and potential for a rebound, with some pointing to the upcoming Chicken Shawarma menu addition as a catalyst. Despite concerns about the consumer environment and past downgrades, the company's expansion plans and debt-free balance sheet remain key talking points.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is trending as the community discusses its momentum and potential catalysts, particularly around its NXXT project and the anticipation of future news. Community members are actively watching for breakouts and accumulation patterns, while also considering the possibility of a future offering. Positive trial results and analyst buy ratings appear to be contributing to the current interest in the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Martin Shkreli is short $OPEN - what&#39;s your take?

Daniel Thompson

Ryker Buck

Annika Singh

Shane Ibarra

Mack Ortega

Kyle Wang

Dustin James

Moses Goodwin

Stocktwits

Opendoor Technologies Inc

Stocktwits Polls

@StocktwitsPolls I&#39;m in it for the stock, don&#39;t care about the figureheads you&#39;re tying to price movement. They&#39;re both just noise.

ZOOLANDER

MacCarthy

Roël

Happylad47

AM VLOGGERS

Rudy Ortiz

StockTwits Web

 I'm in it for the stock, don't care about the figureheads you're tying to price movement. They're both just noise.

Randy

@StocktwitsPolls The bear case for OPEN cannot be built upon previous leadership and strategy. Shkreli bases his thesis around past numbers, leadership, and strategy and future projections of them through his spreadsheet formulas. Love Shkreli but I don’t think the bear thesis is correct on this one. Bulls are not buying OPEN because of past earnings and the leadership of the Board and Carrie. It is a full business transformation being priced in under new board leadership of Rabois and Eric Jackson and a NEW ROCKSTAR CEO!!

Golden Mamba

Qubicle

Grey Wix

StockTwits for iOS

 The bear case for OPEN cannot be built upon previous leadership and strategy. Shkreli bases his thesis around past numbers, leadership, and strategy and future projections of them through his spreadsheet formulas. Love Shkreli but I don’t think the bear thesis is correct on this one. Bulls are not buying OPEN because of past earnings and the leadership of the Board and Carrie. It is a full business transformation being priced in under new board leadership of Rabois and Eric Jackson and a NEW ROCKSTAR CEO!!

@StocktwitsPolls can you guys add a way to change your vote after youve made it I clicked too fast and chose the wrong option lol

 can you guys add a way to change your vote after youve made it I clicked too fast and chose the wrong option lol

whyyoucare

Rigo Avila

DINA SALEHI

Irving Berlin

@StocktwitsPolls Shkreli is a convicted piece of shit.

Abbs

Jakkar Ruus

Son Of The Alamo

Wiley3300k

Juststartingout14

Lisa Michelson

Vincent Hagerty

Robert S Hollomon

Kelvingiang888

Julian

@StocktwitsPolls Martin Shkreli is an American investor and businessman known for co-founding hedge funds like Elea Capital and MSMB Capital, and pharmaceutical companies such as Retrophin and Turing Pharmaceuticals. He gained widespread notoriety in 2015 when, as CEO of Turing, he raised the price of the life-saving antiparasitic drug Daraprim from $13.50 to $750 per pill, which drew strong public criticism. In 2017, Shkreli was convicted on charges of securities fraud related to his hedge funds and was sentenced to seven years in prison with fines. He was released early in May 2022 and is permanently banned from serving as an officer of publicly traded companies. His story is often associated with the nickname &quot;Pharma Bro&quot; due to his controversial practices in the pharmaceutical industry.

True

 Martin Shkreli is an American investor and businessman known for co-founding hedge funds like Elea Capital and MSMB Capital, and pharmaceutical companies such as Retrophin and Turing Pharmaceuticals. He gained widespread notoriety in 2015 when, as CEO of Turing, he raised the price of the life-saving antiparasitic drug Daraprim from $13.50 to $750 per pill, which drew strong public criticism. In 2017, Shkreli was convicted on charges of securities fraud related to his hedge funds and was sentenced to seven years in prison with fines. He was released early in May 2022 and is permanently banned from serving as an officer of publicly traded companies. His story is often associated with the nickname "Pharma Bro" due to his controversial practices in the pharmaceutical industry.

This is like asking Puff Daddy to watch my kids for the weekend.  Hey, convicted scumbag what do you think of the stock.  Not great @Stocktwits  Won&#39;t participate Howie

Lee Benj

Lincoln Griffin

WM Storey

This is like asking Puff Daddy to watch my kids for the weekend.  Hey, convicted scumbag what do you think of the stock.  Not great 